Reversal of anticoagulation effect in patients on a FXa inhibitor (apixaban, rivaroxaban, or edoxaban) who require urgent surgery or procedure, and who have a major risk of bleeding.

• A trial to learn if andexanet alfa is safe and works to limit bleeding in people who take factor 10a inhibitors and urgently need surgery Ended
  2022-501353-37-00 5

Showing 1–1 of 1 trials